An observational study in Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS) and Urinary Frequency, sponsored by Snap Supplements. Completed at 1 site in United States. Open to male participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Snap Supplements · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 25th largest by enrollment of the 37 observational ones that give a count, is one of 9 that started in 2025, is one of 37 observational ones, and was the 188th registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.
Browse Prostatic Hyperplasia studies →29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:
ALPFA Medical · Sites in United States
Ages 45+ · Men only
ProVerum Medical · Sites in United States
Ages 45+ · Men only
Zenflow, Inc. · Sites in United States
Ages 18+ · Men only
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 28 · Phase 4 16
First in 1988; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 250 across 177 observational studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 150 interventional studies, 201 across the 37 observational. Of the 121 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 188 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Snap Supplements as lead sponsor.
Snap Supplements has 1 study filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
14 of the studies in Prostatic Hyperplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04288427Beth Israel Deaconess Medical Center5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | 2026-12-30 |
| NCT05400980Prodeon Medical, IncExpander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath | 2027-01 |
| NCT06224218University of Illinois at ChicagoProstate Single Port & Laser Enucleation Comparison Trial | 2027-01-15 |
| NCT06560476Urotronic Inc.OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH | 2027-03-30 |
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a decentralized, observational pilot study evaluating the potential effects of Snap Supplements Prostate Health on urinary symptoms in men aged 50 years and older. Prostate enlargement and related urinary issues, such as daytime frequency, nighttime urination (nocturia), and urgency, are common with age and may negatively affect quality of life and sleep.
In this study, approximately 50 participants will take three capsules of Snap Supplements Prostate Health nightly for 90 days while completing brief daily surveys using a secure online platform (Alethios). Surveys will track urinary frequency, nocturia, urgency, and sleep quality, with additional questions about product tolerability, satisfaction, and overall experience.
The main goal is to explore whether taking the supplement for 90 days is associated with improvement in urinary symptoms compared with each participant's own baseline. This is a single-group, pre-post study without randomization or placebo. No in-person visits are required; all activities occur at home.
The supplement contains a blend of natural ingredients (such as saw palmetto, beta-sitosterol, nettle root, turmeric, green tea extract, and mushroom extracts) that have been studied for their potential effects on prostate and urinary health. The study will help characterize user experiences in a real-world setting and generate preliminary data to inform future research.
Participation is voluntary, and participants may withdraw at any time. Compensation is provided for completing surveys. Risks are expected to be minimal, with possible mild gastrointestinal or allergic-type reactions.
Study Overview
This is a decentralized, open-label, single-group, pre-post observational pilot study designed to evaluate the association between daily use of Snap Supplements Prostate Health and changes in urinary symptoms in men aged 50 years and older. The study will recruit and follow approximately 50 participants over a 90-day period.
All study activities are conducted remotely through the Alethios digital research platform, which supports electronic informed consent, daily survey reporting, interim/final assessments, and adverse event reporting. No in-person visits or clinical procedures are required.
Background and Rationale
Age-related prostate enlargement (benign prostatic hyperplasia, BPH) is highly prevalent among men over 50 and often associated with lower urinary tract symptoms (LUTS), including daytime frequency, nocturia, and urgency. These symptoms can disrupt sleep and quality of life. While medications exist, some men seek alternative or adjunctive options with fewer side effects.
Snap Supplements Prostate Health is a commercially available dietary supplement containing plant sterols (beta-sitosterol), saw palmetto, nettle root, turmeric (curcumin), reishi and maitake mushroom extracts, and green tea extract. Prior clinical and mechanistic studies suggest these ingredients may support urinary comfort, reduce symptom burden, and promote prostate health. This study aims to evaluate user-reported changes in urinary symptoms during 90 days of nightly supplement use in a real-world, at-home setting.
Objectives
Primary Aim:
To assess whether 90 days of Snap Supplements Prostate Health is associated with improvements in:
Daytime urinary frequency
Nocturia (nighttime urination)
Urinary urgency
Secondary Aims:
Evaluate self-reported sleep quality at baseline, Day 30, Day 60, and Day 90
Collect consumer perceptions regarding symptom relief, satisfaction, daily-life impact, tolerability, and willingness to continue use
Study Design
Type: Single-group, pre-post, observational study
Intervention: 3 capsules of Snap Supplements Prostate Health nightly for 90 consecutive days
Duration: 90 days per participant
Sample size: \~50 men aged 50 years and older
Study site: Fully decentralized, via the Alethios online platform
Eligibility Criteria
Inclusion:
Male, age ≥50
Self-reported urinary symptoms (frequency, nocturia, urgency)
Willing and able to complete daily online surveys for 90 days
Not currently taking other prostate-related supplements or medications (or willing to discontinue)
Exclusion:
History of prostate cancer or urologic disorder requiring treatment
Significant chronic illness affecting urinary function (e.g., uncontrolled diabetes, neurologic conditions)
Known allergies to supplement ingredients (turmeric, nettle root, saw palmetto, mushrooms, green tea)
Current use of medications that interact with curcumin (selected chemotherapy, anticoagulants, immunosuppressants)
Data Collection and Assessments
Baseline: Demographics, medical/supplement history, symptom severity
Daily Surveys: Daytime urinary frequency, nocturia, urgency rating (1-10)
Interim Surveys (Days 30 \& 60): Sleep quality, symptom check
Final Survey (Day 90): Sleep quality, symptom check, consumer perception outcomes (satisfaction, tolerability, daily impact, willingness to continue)
Estimated participant burden: \~1-2 minutes/day for surveys; 5-10 minutes each for interim/final assessments.
Outcomes
Primary Outcomes:
Within-participant change from baseline to Day 90 in urinary frequency (day and night) and urgency
Secondary Outcomes:
Within-participant change in self-reported sleep quality (baseline vs. Day 30, 60, 90)
Descriptive measures of consumer perceptions, tolerability, and satisfaction
Statistical Analysis
Primary analyses: Pre-post comparisons using paired t-tests or Wilcoxon signed-rank tests, as appropriate
Longitudinal analyses: Mixed-effects models with random intercepts to estimate change over time in frequency counts, urgency, and sleep quality
Secondary outcomes: Descriptive summaries and exploratory models for perception and tolerability endpoints
Risks and Benefits
Risks are minimal and primarily include mild gastrointestinal upset, allergic-type reactions, or rare sensitivity to ingredients (e.g., green tea extract, turmeric). Participants are instructed to take capsules with food to minimize risk. Adverse events can be reported 24/7 via the study platform and will be reviewed promptly.
Direct health benefits are not guaranteed. Participants may gain insight into symptom patterns over time. The main benefit is contributing to research on natural approaches to prostate and urinary health.
Confidentiality
Data will be collected and stored via the HIPAA- and 21 CFR Part 11-compliant Alethios platform. Information is de-identified, encrypted, and stored securely. Personally identifiable information (PII) is separated from study data and accessible only to authorized staff.
Compensation
Participants who complete ≥75% of study surveys will receive a $20 Amazon gift card. There are no costs to participants.
Study Timeline
IRB Submission: Within 2 weeks of protocol finalization
Enrollment: \~2-3 weeks post-IRB approval
Data Collection: 90 days per participant
Analysis \& Report: Within 3 months after study completion
Men aged 50 and older with self-reported urinary symptoms consistent with age-related prostate enlargement. Participants must be capable of completing daily online surveys over a 90-day period. Recruitment will occur remotely through online advertising and email outreach, with enrollment and all data collection conducted via the Alethios digital platform.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male, age ≥50 years
Self-reported prostate-related urinary symptoms (daytime frequency, nocturia, urgency)
Able and willing to complete daily surveys for 90 days
Not currently taking prostate-related supplements or medications (or willing to discontinue prior to study)
Exclusion Criteria:
Significant chronic illness affecting urinary function (e.g., uncontrolled diabetes, neurologic conditions)
Known allergy to any study product ingredients (turmeric, nettle root, saw palmetto, green tea, maitake or reishi mushrooms)
Current use of medications likely to influence urinary patterns (e.g., diuretics, alpha-blockers) unless stabilized and documented
Current use of medications known to interact with curcumin (e.g., certain chemotherapies, warfarin/anticoagulants, such as tacrolimus)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take three capsules nightly of a commercially available dietary supplement, Prostate Health (Snap Supplements), for 90 consecutive days. The formulation contains a blend of plant-derived and botanical ingredients that have been studied for potential effects on prostate and urinary health. Key components include: beta-sitosterol and other phytosterols, saw palmetto extract, stinging nettle root extract, turmeric (curcumin), green tea extract (EGCG), reishi mushroom, and maitake mushroom. Participants will self-administer the product at home with water, preferably with food, and record daily urinary symptoms using a secure digital platform. No placebo or comparator is included.
Change in Daytime Urinary Frequency
Number of daytime urinations per 24 hours, self-reported daily using the Alethios survey platform. Change from baseline to Day 90 will be assessed within participants.
Time frame: Baseline to Day 90
Change in Nighttime Urinary Frequency (Nocturia)
Number of times participants wake at night to urinate, self-reported daily. Change from baseline to Day 90 will be assessed within participants.
Time frame: From Baseline to Day 90
Change in Urinary Urgency
Participant-rated urinary urgency on a 1-10 numeric rating scale (higher = greater urgency), reported daily. Change from baseline to Day 90 will be assessed.
Time frame: Baseline to Day 90
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Feb 2026, 4 months.
Of 74 observational studies under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.